Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:ADMA NASDAQ:IMMX NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.87-3.1%$23.01$17.40▼$48.45$1.67B-0.054,548 shs22,674 shsADMAADMA Biologics$7.76+2.1%$9.60$7.21▼$22.37$1.80B0.725.30 million shs2.92 million shsIMMXImmix Biopharma$8.44+1.0%$9.31$1.93▼$11.61$459.23M0.11941,319 shs1.05 million shsRAPPRapport Therapeutics$37.00+6.0%$35.05$10.51▼$42.27$1.77B0.97334,810 shs198,632 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-3.30%-8.35%-20.95%-17.08%-26.84%ADMAADMA Biologics-3.80%-6.75%-27.76%-54.05%-62.80%IMMXImmix Biopharma-9.33%-5.43%-10.11%-2.34%+221.54%RAPPRapport Therapeutics-5.96%-12.11%+2.98%+18.95%+271.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.87-3.1%$23.01$17.40▼$48.45$1.67B-0.054,548 shs22,674 shsADMAADMA Biologics$7.76+2.1%$9.60$7.21▼$22.37$1.80B0.725.30 million shs2.92 million shsIMMXImmix Biopharma$8.44+1.0%$9.31$1.93▼$11.61$459.23M0.11941,319 shs1.05 million shsRAPPRapport Therapeutics$37.00+6.0%$35.05$10.51▼$42.27$1.77B0.97334,810 shs198,632 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-3.30%-8.35%-20.95%-17.08%-26.84%ADMAADMA Biologics-3.80%-6.75%-27.76%-54.05%-62.80%IMMXImmix Biopharma-9.33%-5.43%-10.11%-2.34%+221.54%RAPPRapport Therapeutics-5.96%-12.11%+2.98%+18.95%+271.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.25Buy$46.67168.20% UpsideADMAADMA Biologics 2.20Hold$19.00146.43% UpsideIMMXImmix Biopharma 2.50Moderate Buy$19.50126.48% UpsideRAPPRapport Therapeutics 2.90Moderate Buy$58.8360.97% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, RAPP, ADMA, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026RAPPRapport Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/26/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/21/2026RAPPRapport Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $65.005/18/2026RAPPRapport Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.00 ➝ $56.005/8/2026RAPPRapport Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$53.005/7/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.005/7/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$24.00 ➝ $20.004/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/24/2026AAPGAscentage Pharma Group International Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/22/2026RAPPRapport Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$53.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$82.10M19.78N/AN/A$2.04 per share8.53ADMAADMA Biologics$510.17M3.50$0.64 per share12.08$2.01 per share3.84IMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/ARAPPRapport TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/AADMAADMA Biologics$146.93M$0.6811.347.34N/A32.43%39.98%28.08%8/5/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%6/3/2026 (Estimated)RAPPRapport Therapeutics-$111.48M-$2.60N/AN/AN/AN/A-24.78%-23.44%8/6/2026 (Estimated)Latest IMMX, RAPP, ADMA, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q1 2026IMMXImmix Biopharma-$0.2084N/AN/AN/AN/AN/A5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A5/7/2026Q1 2026RAPPRapport Therapeutics-$0.56-$0.42+$0.14-$0.42$7.50 million$20.00 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million3/25/2026Q4 2025AAPGAscentage Pharma Group InternationalN/A-$0.5150N/A-$0.5150N/A$24.72 million3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/10/2026Q4 2025RAPPRapport Therapeutics-$0.65-$0.72-$0.07-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77ADMAADMA Biologics0.516.953.93IMMXImmix BiopharmaN/A8.758.75RAPPRapport TherapeuticsN/A27.0827.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AADMAADMA Biologics75.68%IMMXImmix Biopharma11.26%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AADMAADMA Biologics3.90%IMMXImmix Biopharma30.30%RAPPRapport Therapeutics12.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.33 millionN/AN/AADMAADMA Biologics530231.77 million222.73 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableRAPPRapport TherapeuticsN/A47.83 million41.86 millionN/AIMMX, RAPP, ADMA, and AAPG HeadlinesRecent News About These CompaniesRapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells $743,808.60 in StockMay 31 at 4:59 AM | americanbankingnews.comRock Ventures L.P. Third Sells 18,572 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMay 29, 2026 | insidertrades.comSwedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPPMay 28, 2026 | marketbeat.comRapport Therapeutics Inc RAPPMay 27, 2026 | morningstar.comMRapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 24, 2026 | americanbankingnews.comRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceMay 20, 2026 | globenewswire.comUBS Group AG Sells 331,713 Shares of Rapport Therapeutics, Inc. $RAPPMay 20, 2026 | marketbeat.comRapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTradingMay 19, 2026 | theglobeandmail.comBTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)May 17, 2026 | theglobeandmail.comVanguard Group Inc. Acquires 191,219 Shares of Rapport Therapeutics, Inc. $RAPPMay 16, 2026 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells $5,376,788.32 in StockMay 14, 2026 | insidertrades.comRock Ventures L.P. Third Sells 5,018 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMay 12, 2026 | insidertrades.comRapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street ZenMay 9, 2026 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Posts Earnings Results, Beats Estimates By $0.25 EPSMay 8, 2026 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Receives Buy Rating from BTIG ResearchMay 8, 2026 | marketbeat.comRapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure MarketMay 7, 2026 | tipranks.comRapport Therapeutics, Inc. (RAPP) Reports Q1 LossMay 7, 2026 | zacks.comRapport Therapeutics Reports First Quarter 2026 Financials and Provides Business UpdateMay 7, 2026 | globenewswire.comRapport Therapeutics Insiders Added US$1.61m Of Stock To Their HoldingsApril 30, 2026 | finance.yahoo.comModalités de mise à disposition du rapport financier annuel 2025April 30, 2026 | globenewswire.comMISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025April 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026Quantum Stocks Just Got a Lifeline—Who Benefits Most?By Nathan Reiff | May 26, 2026What IBM's $10-Billion Quantum Project Means For Smaller PlayersBy Nathan Reiff | June 3, 2026IMMX, RAPP, ADMA, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$17.87 -0.58 (-3.14%) Closing price 03:59 PM EasternExtended Trading$17.79 -0.08 (-0.45%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.ADMA Biologics NASDAQ:ADMA$7.76 +0.16 (+2.11%) Closing price 04:00 PM EasternExtended Trading$7.73 -0.03 (-0.34%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Immix Biopharma NASDAQ:IMMX$8.44 +0.08 (+0.96%) Closing price 04:00 PM EasternExtended Trading$8.63 +0.19 (+2.25%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Rapport Therapeutics NASDAQ:RAPP$37.00 +2.10 (+6.02%) Closing price 04:00 PM EasternExtended Trading$38.50 +1.50 (+4.05%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
